SPECIAL NOTICE
99 -- NCI OA Special Notice of Subcontract Opportunity at the Frederick National Laboratory for Cancer Research
- Notice Date
- 10/31/2023 10:43:57 AM
- Notice Type
- Special Notice
- Contracting Office
- NIH NCI Bethesda MD 20892 USA
- ZIP Code
- 20892
- Response Due
- 11/24/2023 9:00:00 AM
- Archive Date
- 12/09/2023
- Point of Contact
- Jennifer Gnuschke
- E-Mail Address
-
jennifer.gnuschke@nih.gov
(jennifer.gnuschke@nih.gov)
- Description
- This Special Notice is not a formal Invitation for Bid (IFB), Request for Proposal (RFP), Request for Quotation (RFQ) nor any type of Solicitation for offers. In accordance with FAR 15.201(d), this Special Notice is intended FOR INFORMATIONAL PURPOSES ONLY in order to publicize the requirements of the Frederick National Laboratory for Cancer Research (FNLCR). The FNLCR is a Government-Owned Contractor-Operated Federally Funded Research and Development Center (FFRDC) located at Fort Detrick, Maryland. The FNLCR partners with university, Government, and corporate scientists to speed the translation of laboratory research into new diagnostic tests and treatments for cancer and AIDS. FNLCR is a multi-program laboratory currently operated by Leidos Biomedical Research, Inc. (Leidos Biomed) for the National Cancer Institute (NCI) under Prime Contract No. 75N91019D00024, which provides Operations and Technical Support (OTS) for the FNLCR. The Government assumes no liability for reimbursement for any effort or associated costs to respond, nor for any information provided as a result of this Special Notice as no information is being requested. Please be advised that any submissions provided, despite that no information is requested, become Government property and will not be returned, nor will there be any ensuing discussions or debriefings. Responses submitted to this Special Notice are not offers and cannot be accepted by the U.S. Government to form a binding contract. It is the responsibility of the interested parties to monitor this site and any sites referenced herein for additional information pertaining to business opportunities with the FNLCR, if any. Scope of Work Leidos Biomed seeks consultation to deliver a report detailing the facility design recommendations, preferred equipment, regulatory compliance considerations, and a cost estimate for implementation of a nucleic acid synthesis capability, including oligonucleotide synthesis, oligonucleotide processing and gene construction, plasmid cloning and sequence confirmation.� A baseline capability would be 50 new plasmids annually, with a high-throughput capability handling >1,000 new plasmids.� Resulting plasmids would be used for research or to generate stable cell lines, eventually leading to GMP cell banks for future GMP pDNA or protein production.� High-throughput mRNA synthesis would also be evaluated.� Objectives and Project Requirements Participate in a project kickoff meeting. Kickoff will take place at a time and location that is mutually agreeable to participants. Consultant will present their approach and technical execution plan for the project. Evaluate VPP facilities and capacity for nucleic acid synthesis work. Evaluation shall include on-site visit to the current VPP laboratories in Gaithersburg, MD and/or proposed location where nucleic acid synthesis may take place in the Gaithersburg, MD area.� The on-site evaluation could be aligned with the project kickoff timing, if practical for all parties. Participate in periodic meetings with VPP (on-site or virtual, as necessary) to provide project updates and gather information needed to complete the evaluation. Generate a report that outlines a strategic plan for designing, implementing, and executing a high-throughput nucleic acid synthesis capability for DNA and RNA production. Capability is limited to non-GMP reagent production as well as precursor materials for GMP activities (e.g., plasmid DNA may be used to generate stable cell lines, which will then be used in production of GMP cell banks for future GMP production). Strategic report shall include a thorough evaluation of facility, equipment, regulatory, and resource needs for operating a nucleic acid facility capable of producing 50 new plasmid constructs (initial capability) with potential to achieve a high-throughput capacity of up to 1,000 new plasmids annually. Leidos Biomedical Research, Inc. Point of Contact for a copy of Solicitation/RFP No: S24-004: Jennifer Gnuschke at jennifer.gnuschke@nih.gov ��
- Web Link
-
SAM.gov Permalink
(https://sam.gov/opp/f1cb4cc42fc0479d8a0429821d413ee5/view)
- Record
- SN06871870-F 20231102/231031230047 (samdaily.us)
- Source
-
SAM.gov Link to This Notice
(may not be valid after Archive Date)
| FSG Index | This Issue's Index | Today's SAM Daily Index Page |